Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-BLADDER01 in metastatic urothelial cancer after immunotherapy
2025-522400-24-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in transitional cell carcinoma (TCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Phase 2 decision endpoint, Progression-free survival and 1 more. Planned start Jan 2026; status: authorised.
02
Drugs
izalontamab brengitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2025-522400-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522400-24-00.